Prognostic factors and survival in metastatic breast cancer: A single institution experience

Reports of Practical Oncology and Radiotherapy

Volumn 18, Issue 3, 2013, Pages 127-132

  Khanfir, Afef ^a   Lahiani, Faiez ^a   Bouzguenda, Racem ^a   Ayedi, Ines ^a   Daoud, Jamel ^a   Frikha, Mounir ^a  

^a HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

Breast cancer; Metastasis; Prognostic factors; Survival

Indexed keywords

ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; HORMONE RECEPTOR; NAVELBINE; PAMIDRONIC ACID; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

AGE DISTRIBUTION; BONE METASTASIS; BREAST METASTASIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE INTERVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OVERALL SURVIVAL; PRIMARY TUMOR; REVIEW; RISK FACTOR; VISCERAL METASTASIS;

EID: 84878211914     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2013.01.001     Document Type: Review

References (34)

1. Khanfir A., Frikha M., Kallel F., et al. Breast cancer in young women in the south of Tunisia. Cancer/Radiother 2006, 10(8):565-571.
2. Dawood S., Broglio K., Ensor J., Hortobagyi G.N., Giordano S.H. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010, 21(11):2169-2174.
3. Fodor J., Major T., József T., Zoltán S., Csaba P. Comparison of mastectomy with breast-conserving surgery in invasive lobular carcinoma: 15-year results. Rep Pract Oncol Radiother 2011, 16(6):227-231.
4. Ulukaya E., Karaagac E., Ari F., et al. Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients. Radiol Oncol 2011, 45(2):116-122.
5. Algara M., Arenas M., De las Peñas Eloisa Bayo D., et al. Radiation techniques used in patients with breast cancer: results of a survey in Spain. Rep Pract Oncol Radiother 2012, 17(3):122-128.
6. Atalay G., Biganzoli L., Renard F., et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective randomized metastatic breast cancer trials. Eur J Cancer 2003, 39(17):2439-2449.
7. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005, 23(19):4265-4274.
8. Nisticò C., Cuppone F., Bria E., et al. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. Anticancer Drugs 2006, 17(10):1193-1200.
9. Ernst M.F., van de Poll-Franse L.V., Roukema J.A., et al. Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast 2007, 16(4):344-351.
10. Er O., Frye D.K., Kau S.W., et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008, 14(1):62-68.
11. Largillier R., Ferrero J.M., Doyen J., et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 2008, 19(12):2012-2019.
12. Hortobagyi G.N., Smith T.L., Legha S.S., et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983, 1(12):776-786.
13. Aisner J., Cirrincione C., Perloff M., et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast a randomized phase III trial comparing CAF versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol 1995, 13(6):1443-1452.
14. Dhodapkar M.V., Ingle J.N., Cha S.S., Mailliard J.A., Wieand H.S. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Cancer 1996, 77(4):683-690.
15. Luoma M.L., Hakamies-Blomqvist L., Sjöström J., et al. Prognostic value of quality of life scores for time to progression (TTP) and OS time (OS) in advanced breast cancer. Eur J Cancer 2003, 39(10):1370-1376.
16. Cardoso F., Di La, Lohrisch C., Bernard C., Ferreira F., Piccart M.J. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 2002, 13(2):197-207.
17. Bastholt L., Dalmark M., Gjedde S.B., et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996, 14(4):1146-1155.
18. Blanco G., Holli K., Heikkinen M., Kallioniemi O.P., Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 1990, 62(1):142-146.
19. Venturini M., Bruzzi P., Del Mastro L., et al. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996, 14(3):764-773.
20. Vogel C.L., Azevedo S., Hilsenbeck S., East D.R., Ayub J. Survival after first recurrence of breast cancer, the Miami experience. Cancer 1992, 70(1):129-135.
21. Chang J., Clark G.M., Allred D.C., Mohsin S., Chamness G., Elledge R.M. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003, 97(3):545-553.
22. Coleman R.E., Purohit O.P., Vinholes J.J., Zekri J. High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997, 80(8 Suppl.):1686-1690.
23. SaartoT, Janes R., Tenhunen M., Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 2002, 6(5):323-330.
24. ®: a place for biological tools?. Immunoanal Biol Spécial 2007, 22(3):151-155.
25. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987, 55(1):61-66.
26. Pentheroudakis G., Fountzilas G., Bafaloukos D., et al. Metastatic breast cancer with liver metastases: a registry analysis of clinic pathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 2006, 97(3):237-244.
27. Schlappack O.K., Baur M., Steger G., Dittrich C., Moser K. The clinical course of lung metastases from breast cancer. Klin Wochenschr 1988, 66(17):790-795.
28. Wadasadawala T., Gupta S., Bagul V., Patil N. Brain metastases from breast cancer: management approach. J Cancer Res Ther 2007, 3(3):157-165.
29. Curtin J.P., Barakat R.R., Hoskins W.J. Ovarian disease in women with breast cancer. Obstet Gynecol 1994, 84(3):449-452.
30. Eitan R., Gemignani M.L., Venkatraman E.S., Barakat R.R., Abu-Rustum N.R. Breast cancer metastatic to abdomen and pelvis: role of surgical resection. Gynecol Oncol 2003, 90(2):397-401.
31. Gnerlich J., Jeffe D.B., Deshpande A.D., Beers C., Zander C., Margenthaler J.A. Surgical removal of the primary tumor increases OS in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol 2007, 14(8):2187-2194.
32. Rao R., Feng L., Kuerer H.M., Singletary S.E., Bedrosian I., Hunt K.K., et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008, 15(6):1696-1702.
33. Le Scodan R., Stevens D., Brain E., et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 2009, 27(9):1375-1381.
34. Wong M.H., Stockler M.R., Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012, 2:CD003474.